S&N sells wound care products
This article was originally published in The Gray Sheet
Executive Summary
Advanced BioHealing acquires Smith & Nephew's Dermagraft tissue-engineered dermal replacement product for full-thickness diabetic foot ulcers and TransCyte temporary wound cover for serious burns. The May 31 product purchase, for undisclosed terms, dovetails with the start-up firm's R&D efforts in tissue engineering; the firm has a pending IDE for a keratinocyte-based bioengineered wound covering that does not require deep frozen storage. S&N indicated its interest in divesting the products in October 2005 to boost its "growth profile" after receiving an FDA "non-approvable" letter for an expanded Dermagraft indication to treat venous leg ulcers...
You may also be interested in...
Financings In Brief
Device VC activity increases
Jemperli Results In Endometrial Cancer Help GSK Build ‘Backbone’ In Immunotherapy
Latecomer PD-1/L1 drug Jemperli has achieved impressive Phase III results in first line endometrial cancer, and GSK hopes it can “redefine” care, especially in dMMR patients. Rival Merck, however, has other ideas.
Pipeline Watch - ADD Meeting Dominates Phase III Readouts
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.